CN104971252A - Pharmaceutical composition for treating postnatal blood deficiency-heat - Google Patents

Pharmaceutical composition for treating postnatal blood deficiency-heat Download PDF

Info

Publication number
CN104971252A
CN104971252A CN201510425324.4A CN201510425324A CN104971252A CN 104971252 A CN104971252 A CN 104971252A CN 201510425324 A CN201510425324 A CN 201510425324A CN 104971252 A CN104971252 A CN 104971252A
Authority
CN
China
Prior art keywords
parts
radix
herba
pharmaceutical composition
heat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510425324.4A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN104971252A publication Critical patent/CN104971252A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to a pharmaceutical composition for treating postnatal blood deficiency-heat. The pharmaceutical composition is prepared from the following substances in parts by weight: 10-20 parts of astragalus membranaceus, 5-15 parts of poria cocos, 10-20 parts of cynanchum thesioides, 1-10 parts of hairyvein agrimony, 10-20 parts of holothuria leucospilota, 5-15 parts of prepared fleece flower roots, 1-10 parts of lindera megaphylla, 5-15 parts of bighead atractylodes rhizome, 10-20 parts of firethorn fruits, 10-20 parts of cortex lycii radicis, 1-10 parts of round-leaved mint leaves, 5-15 parts of monthly rose, 10-20 parts of bulbil, 10-20 parts of embelia parviflora, 5-15 parts of gordon euryale leaves, 1-10 parts of Chinese wax, 10-20 parts of hedyotis caudatifolia, 1-10 parts of tylorrhynchus, 5-15 parts of limonite, 5-15 parts of meadow saxifrage, 10-20 parts of Chinese Silvergrass fruits and 1-10 parts of liquorice. The pharmaceutical composition is capable of nourishing blood, invigorating qi, harmonizing ying, clearing heat, and invigorating the spleen and stomach, and is significant in treatment effect on postnatal blood deficiency-heat and worthy of clinical application and popularization.

Description

A kind of pharmaceutical composition for the treatment of hemopenia fever in puerperal
The divisional application of the patent of " a kind of pharmaceutical composition for the treatment of hemopenia fever in puerperal " that the present invention is application number is 201510066306.1, the applying date, to be February 10, denomination of invention in 2015 be.
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of pharmaceutical composition for the treatment of hemopenia fever in puerperal.
Background technology
Heating is common disease clinically.Western medicine thinks that heating is that the body temperature caused by pyrogen raises, and treats based on ntipyretic analgesic medicine, optionally for pathogen administration of antibiotics class medicine.Heating is then divided into fever caused by exogenous pathogens and the large class of fever due to internal injury two by Chinese medicine.Different according to the cause of disease and the clinical symptoms of heating, it is dissimilar that fever due to internal injury comprises again the deficiency of vital energy, blood deficiency, the deficiency of YIN, yang deficiency, blood addiction, stagnate etc.Hemopenia fever is because of the heating caused by blood deficiency, tells that nosebleed is had blood in stool, metrorrhagia in puerperal or improper diet and overtiredness disorder of the spleen and stomach caused by internal damage all can cause hemopenia fever.The clinical manifestation of hemopenia fever has following several feature: (1) is common with low grade fever, and high heat also can appear in a few patients; (2) course of disease is longer, and often long-time low grade fever does not move back; (3) fever time is many in the afternoon to night; (4) patient's, menoxenia thin and delicate with shallow complexion or light Bai Buze, palpitation with irritability, insomnia and dreamful sleep, limb paralysis, lip pale tongue, pulse condition etc.
Puerpera is more owing to losing blood in production process, very easily causes hemopenia fever.Chinese medicine is thought, thin fluid injury, and cloudy blood is suddenly empty, and sun, without complied with, outside empty sun more floats on, is the Etiological of hemopenia fever in puerperal.Because puerpera's body constitution is comparatively special, therefore use the simple antipyretic-antalgic therapy for febrile conditions to be far from being enough, and Chinese medical discrimination therapy is by the merit of qi-supplementing, blood-engendering, stomach warming spleen invigorating, treatment hemopenia fever syndrome is comparatively effective, and safe and reliable, treating both the principal and secondary aspects of a disease.
Summary of the invention
The object of this invention is to provide a kind of pharmaceutical composition for the treatment of hemopenia fever in puerperal.
In order to realize object of the present invention, the invention provides a kind of pharmaceutical composition for the treatment of hemopenia fever in puerperal, it is made up of the material of following weight portion: Radix Astragali 10-20 part, Poria 5-15 part, Herba Cynanchi Thesioidis 10-20 part, Herba Agrimoniae 1-10 part, swing skin ginseng 10-20 part, Radix Polygoni Multiflori Preparata 5-15 part, Lindera megaphylla 1-10 part, Rhizoma Atractylodis Macrocephalae 5-15 part, Fructus Pyracanthae (Fructus Pyracanthae Fortuneanae) 10-20 part, Cortex Lycii 10-20 part, Radix Menthae Rotundifoliae 1-10 part, Flos Rosae Chinensis 5-15 part, Bulbilus dioscoreae 10-20 part, Radix seu Caulis Embeliae Parviflorae 10-20 part, Folium Euryales 5-15 part, Cera Chinensis 1-10 part, Herba Hedyotis Lanceae 10-20 part, Tylorrhynchus heterochaeta Quatrefages 1-10 part, Limonitum 5-15 part, Herba Seselis Seseloidis 5-15 part, Miscanthus floridulus (Labill.) Warb. 10-20 part, Radix Glycyrrhizae 1-10 part.
Preferably, of the present invention treatment puerperal hemopenia fever pharmaceutical composition be made up of the material of following weight portion: the Radix Astragali 15 parts, 10 parts, Poria, Herba Cynanchi Thesioidis 12 parts, Herba Agrimoniae 5 parts, swing skin join 15 parts, Radix Polygoni Multiflori Preparata 10 parts, Lindera megaphylla 8 parts, the Rhizoma Atractylodis Macrocephalae 12 parts, Fructus Pyracanthae (Fructus Pyracanthae Fortuneanae) 15 parts, Cortex Lycii 12 parts, Radix Menthae Rotundifoliae 5 parts, Flos Rosae Chinensis 10 parts, Bulbilus dioscoreae 15 parts, Radix seu Caulis Embeliae Parviflorae 15 parts, Folium Euryales 12 parts, Cera Chinensis 5 parts, Herba Hedyotis Lanceae 15 parts, Tylorrhynchus heterochaeta Quatrefages 10 parts, Limonitum 12 parts, Herba Seselis Seseloidis 10 parts, Miscanthus floridulus (Labill.) Warb. 15 parts, 9 parts, Radix Glycyrrhizae.
More preferably, described pharmaceutical composition can be tablet, dispersible tablet, capsule, soft capsule or patch.
The present invention also provides the purposes of compositions in the medicine of preparation treatment hemopenia fever in puerperal, described compositions is made up of the material of following weight portion: Radix Astragali 10-20 part, Poria 5-15 part, Herba Cynanchi Thesioidis 10-20 part, Herba Agrimoniae 1-10 part, swing skin ginseng 10-20 part, Radix Polygoni Multiflori Preparata 5-15 part, Lindera megaphylla 1-10 part, Rhizoma Atractylodis Macrocephalae 5-15 part, Fructus Pyracanthae (Fructus Pyracanthae Fortuneanae) 10-20 part, Cortex Lycii 10-20 part, Radix Menthae Rotundifoliae 1-10 part, Flos Rosae Chinensis 5-15 part, Bulbilus dioscoreae 10-20 part, Radix seu Caulis Embeliae Parviflorae 10-20 part, Folium Euryales 5-15 part, Cera Chinensis 1-10 part, Herba Hedyotis Lanceae 10-20 part, Tylorrhynchus heterochaeta Quatrefages 1-10 part, Limonitum 5-15 part, Herba Seselis Seseloidis 5-15 part, Miscanthus floridulus (Labill.) Warb. 10-20 part, Radix Glycyrrhizae 1-10 part.
Preferably, described compositions is made up of the material of following weight portion: the Radix Astragali 15 parts, 10 parts, Poria, Herba Cynanchi Thesioidis 12 parts, Herba Agrimoniae 5 parts, swing skin join 15 parts, Radix Polygoni Multiflori Preparata 10 parts, Lindera megaphylla 8 parts, the Rhizoma Atractylodis Macrocephalae 12 parts, Fructus Pyracanthae (Fructus Pyracanthae Fortuneanae) 15 parts, Cortex Lycii 12 parts, Radix Menthae Rotundifoliae 5 parts, Flos Rosae Chinensis 10 parts, Bulbilus dioscoreae 15 parts, Radix seu Caulis Embeliae Parviflorae 15 parts, Folium Euryales 12 parts, Cera Chinensis 5 parts, Herba Hedyotis Lanceae 15 parts, Tylorrhynchus heterochaeta Quatrefages 10 parts, Limonitum 12 parts, Herba Seselis Seseloidis 10 parts, Miscanthus floridulus (Labill.) Warb. 15 parts, 9 parts, Radix Glycyrrhizae.
More preferably, described medicine can be tablet, dispersible tablet, capsule, soft capsule or patch.
In the present compositions, Herba Hedyotis Lanceae, Tylorrhynchus heterochaeta Quatrefages, Miscanthus floridulus (Labill.) Warb. are monarch drug; The Radix Astragali, Poria, Herba Cynanchi Thesioidis, Herba Agrimoniae, swing skin ginseng, Radix Polygoni Multiflori Preparata is ministerial drug; Lindera megaphylla, the Rhizoma Atractylodis Macrocephalae, Fructus Pyracanthae (Fructus Pyracanthae Fortuneanae), Cortex Lycii, Radix Menthae Rotundifoliae, Flos Rosae Chinensis, Bulbilus dioscoreae, Radix seu Caulis Embeliae Parviflorae, Folium Euryales, Cera Chinensis, Limonitum, Herba Seselis Seseloidis are adjuvant drug; Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription, for making medicine.
Pharmaceutical composition of the present invention, based on the relation of yang blood and qi, to be brought down a fever based on nourishing blood and invigorating qi, He Ying, warming and invigorating the spleen and stomach, is aided with clearing away heat to stop bleeding, menstruction regulating and pain relieving, treatment hemopenia fever Be very effective in puerperal, clinic application and promoting.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Unless otherwise stated, the percent in the present invention is percetage by weight.
The preparation of embodiment pharmaceutical composition of the present invention
For patch, the preparation technology of pharmaceutical composition of the present invention is as follows:
Take the Radix Astragali 150 grams, 100 grams, Poria, Herba Cynanchi Thesioidis 120 grams, Herba Agrimoniae 50 grams, swing skin and join 150 grams, Radix Polygoni Multiflori Preparata 100 grams, Lindera megaphylla 80 grams, the Rhizoma Atractylodis Macrocephalae 120 grams, Fructus Pyracanthae (Fructus Pyracanthae Fortuneanae) 150 grams, Cortex Lycii 120 grams, Radix Menthae Rotundifoliae 50 grams, Flos Rosae Chinensis 100 grams, Bulbilus dioscoreae 150 grams, Radix seu Caulis Embeliae Parviflorae 150 grams, Folium Euryales 120 grams, Cera Chinensis 50 grams, Herba Hedyotis Lanceae 150 grams, Tylorrhynchus heterochaeta Quatrefages 100 grams, Limonitum 120 grams, Herba Seselis Seseloidis 100 grams, Miscanthus floridulus (Labill.) Warb. 150 grams, 90 grams, Radix Glycyrrhizae, pulverize, cross 100 mesh sieves, add 3000 grams, vaseline, stir, spread upon on non-woven fabrics, evenly be cut into 100 pieces.
The curative effect of experimental example pharmaceutical composition of the present invention
1 data and method
1.1 physical data
This group hemopenia fever in puerperal patient 90 example, is divided into treatment group 50 example and matched group 40 example at random.The treatment group age between 21-37 year, 30.8 years old mean age; Wherein natural labor 19 example, Cesarean esction 31 example.The matched group mean age between 23-38,31.4 years old mean age; Wherein natural labor 14 example, Cesarean esction 26 example.The no significant difference (p > 0.05) of two groups of patient ages and childbirth options, has comparability.
1.2 diagnostic criteria
1.2.1 disease diagnostic criteria
All patients all meet the diagnostic criteria in " new Chinese medicine guideline of clinical investigations ": 1. generate heat.Body temperature >=37.5 DEG C (auxillary temperature), measure every day 4 times (when 2,8 time, 14 time, 20 time); 2. syndrome of deficiency of blood.Primary symptom: pale white complexion or sallow, dizziness and blurred vision, cardiopalmus; Secondary disease: insomnia, numb hand and foot, thready pulse, light red tongue.Possess above-mentioned primary symptom 2 and can specify syndrome of deficiency of blood diagnosis with time disease more than 2 persons.
1.2.2 disease scalar quantization is marked
According to " new Chinese medicine guideline of clinical investigations ", carry out the scoring of disease scalar quantization with the method for patient's readme according to table 1 below:
Table 1 hemopenia fever disease scalar quantization grade form
1.3 Therapeutic Method
Treatment group uses the patch prepared in embodiment to treat, every day 2 times, each forehead using one piece of patch to be attached to patient.The oral Renshen Guipi Wan of matched group (strong spring board, Tianjin Darentang Pharmaceutical Factory is produced), 1 ball/time, 2 times/day.Two groups was all a course for the treatment of with 7 days, treated a course for the treatment of.
1.4 criterion of therapeutical effect
After treatment, the body temperature numerical value of the 1st, 3,5,7 day record two groups of patients, calculates therapeutic index (N) and effective percentage according to the Quantitative marking score value before and after treatment.
Criterion of therapeutical effect is formulated as follows according to " new Chinese medicine guideline of clinical investigations ".Recovery from illness: temperature recovery is normal, and blood deficiency symptom, sign disappear substantially, N >=95%; Effective: temperature recovery is normal, and blood deficiency symptom, sign are obviously improved, N >=75%; Take a turn for the better: temperature decline but still higher than normally, blood deficiency symptom, sign all take a favorable turn, N >=30%; Invalid: body temperature does not decline, higher than normally, blood deficiency symptom, sign are not improved, N < 30%.Wherein:
Score value × 100% before N=(before treatment the rear score value of score value-treatment)/treatment
Effective percentage=(cure+effective+take a turn for the better) number of cases/total number of cases × 100%
1.5 statistical analysis
Adopt the capable statistical analysis of SPSS18.0 software.Measurement data represents with x ± s, adopts t inspection; Enumeration data adopts x 2inspection.With p < 0.05 for difference has statistical significance.
2 results
2.1 Temperature changing
Two groups of patients body temperature no significant difference before the treatment (p > 0.05), and the body temperature of the 3rd, 5,7 day all had decline compared with the 1st day after treatment, difference all has statistical significance (p<0.05), and compared with matched group, treatment group declines more obvious the 5th day and the 7th day, group difference has statistical significance (p<0.05).Specifically in table 2.
The comparison of table 2 liang group patient temperature change
Note: compare with before treatment, * p<0.05; Compare with matched group, * * p<0.05
2.2 scoring score value changes
Two groups of patients scoring score value not statistically significant (p > 0.05) before the treatment, and after treating 7 days, the scoring score value of two groups declines all to some extent, difference has statistical significance (p<0.05), and treatment group comparatively matched group decline more obvious, group difference has statistical significance (p<0.05).Specifically in table 3.
Table 3 liang group patient marks the comparison of score value change
Note: compare with before treatment, * p<0.05; Compare with matched group, * * p<0.05
2.3 effective percentage
Table 4 is below shown in two groups of efficient interpretations of result.Through x 2inspection, the effective percentage of two groups of patients after treatment has significant difference (p<0.05).
A table 4 liang group effective percentage compares
Note: compare with matched group, * p<0.05
Above result shows, the improvement for the treatment of group symptom is all better than matched group, and pharmaceutical composition of the present invention has significant advantage in hemopenia fever in treatment puerperal.

Claims (3)

1. the purposes of compositions in the medicine of preparation treatment hemopenia fever in puerperal, it is characterized in that, described compositions is made up of the material of following weight portion: Radix Astragali 10-20 part, Poria 5-15 part, Herba Cynanchi Thesioidis 10-20 part, Herba Agrimoniae 1-10 part, swing skin ginseng 10-20 part, Radix Polygoni Multiflori Preparata 5-15 part, Lindera megaphylla 1-10 part, Rhizoma Atractylodis Macrocephalae 5-15 part, Fructus Pyracanthae (Fructus Pyracanthae Fortuneanae) 10-20 part, Cortex Lycii 10-20 part, Radix Menthae Rotundifoliae 1-10 part, Flos Rosae Chinensis 5-15 part, Bulbilus dioscoreae 10-20 part, Radix seu Caulis Embeliae Parviflorae 10-20 part, Folium Euryales 5-15 part, Cera Chinensis 1-10 part, Herba Hedyotis Lanceae 10-20 part, Tylorrhynchus heterochaeta Quatrefages 1-10 part, Limonitum 5-15 part, Herba Seselis Seseloidis 5-15 part, Miscanthus floridulus (Labill.) Warb. 10-20 part, Radix Glycyrrhizae 1-10 part.
2. purposes according to claim 1, wherein said compositions is made up of the material of following weight portion: the Radix Astragali 15 parts, 10 parts, Poria, Herba Cynanchi Thesioidis 12 parts, Herba Agrimoniae 5 parts, swing skin join 15 parts, Radix Polygoni Multiflori Preparata 10 parts, Lindera megaphylla 8 parts, the Rhizoma Atractylodis Macrocephalae 12 parts, Fructus Pyracanthae (Fructus Pyracanthae Fortuneanae) 15 parts, Cortex Lycii 12 parts, Radix Menthae Rotundifoliae 5 parts, Flos Rosae Chinensis 10 parts, Bulbilus dioscoreae 15 parts, Radix seu Caulis Embeliae Parviflorae 15 parts, Folium Euryales 12 parts, Cera Chinensis 5 parts, Herba Hedyotis Lanceae 15 parts, Tylorrhynchus heterochaeta Quatrefages 10 parts, Limonitum 12 parts, Herba Seselis Seseloidis 10 parts, Miscanthus floridulus (Labill.) Warb. 15 parts, 9 parts, Radix Glycyrrhizae.
3. purposes according to claim 1 and 2, wherein said medicine can be tablet, dispersible tablet, capsule, soft capsule or patch.
CN201510425324.4A 2015-02-10 2015-02-10 Pharmaceutical composition for treating postnatal blood deficiency-heat Pending CN104971252A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510066306.1A CN104606553B (en) 2015-02-10 2015-02-10 A kind of pharmaceutical composition for the treatment of hemopenia fever in puerperal

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201510066306.1A Division CN104606553B (en) 2015-02-10 2015-02-10 A kind of pharmaceutical composition for the treatment of hemopenia fever in puerperal

Publications (1)

Publication Number Publication Date
CN104971252A true CN104971252A (en) 2015-10-14

Family

ID=53141374

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510425324.4A Pending CN104971252A (en) 2015-02-10 2015-02-10 Pharmaceutical composition for treating postnatal blood deficiency-heat
CN201510066306.1A Expired - Fee Related CN104606553B (en) 2015-02-10 2015-02-10 A kind of pharmaceutical composition for the treatment of hemopenia fever in puerperal

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510066306.1A Expired - Fee Related CN104606553B (en) 2015-02-10 2015-02-10 A kind of pharmaceutical composition for the treatment of hemopenia fever in puerperal

Country Status (1)

Country Link
CN (2) CN104971252A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101112518A (en) * 2007-08-29 2008-01-30 北京艺信堂医药研究所 Chinese traditional medicine preparations for treating postpartum blood deficiency and fever
CN102579799A (en) * 2012-03-06 2012-07-18 蒋月芳 Traditional Chinese medicine composition for treating postpartum fever with blood deficiency

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020008725A (en) * 2000-07-25 2002-01-31 유종근 Health Drink of JEBICHA Using the Pumpkin and Medicinal Herbs and Manufacturi ng Method Thereof
CN101513519B (en) * 2008-02-22 2011-09-28 北京亚东生物制药有限公司 Chinese medicinal composition for invigorating Qi and nourishing blood, preparation method and quality control method thereof
CN103230548B (en) * 2013-05-06 2014-07-16 孙永权 Traditional Chinese medicine composition for treating pulmonary heart disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101112518A (en) * 2007-08-29 2008-01-30 北京艺信堂医药研究所 Chinese traditional medicine preparations for treating postpartum blood deficiency and fever
CN102579799A (en) * 2012-03-06 2012-07-18 蒋月芳 Traditional Chinese medicine composition for treating postpartum fever with blood deficiency

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
关桂霞等: "四物汤加味治疗产后血虚发热15例", 《吉林中医药》 *
史学瑞: "自拟十味汤辨治产后血虚发热", 《河南中医药学刊》 *

Also Published As

Publication number Publication date
CN104606553B (en) 2015-09-23
CN104606553A (en) 2015-05-13

Similar Documents

Publication Publication Date Title
CN103432545A (en) Medicament for allaying fever of child and preparation method thereof
CN101670011A (en) Medicament for treating rheumatism and rheumatoid and preparation method thereof
CN104524287A (en) Traditional Chinese medicinal composition for treating anaphylactoid purpura and preparation method of traditional Chinese medicinal composition
CN103656122B (en) Chinese medicine for the treatment of fever caused by exogenous pathogenic factors and preparation method thereof
CN105031454A (en) Medicine for treating pulmonary tuberculosis
CN104940485A (en) Traditional Chinese medicine composition for treating infantile asthma and preparation method thereof
CN103211990A (en) Chinese medicinal composition for treating oral ulcer
CN103285284B (en) Medical composition for treating senile vaginitis
CN104306662A (en) Traditional Chinese medicine composition for treating neurasthenia and preparation method thereof
CN103520697A (en) Traditional Chinese medicine for treating qi-yin deficiency syndrome type chest stuffiness and pains
CN102579677A (en) Chinese medicinal composition for treating brain glioma
CN104606553B (en) A kind of pharmaceutical composition for the treatment of hemopenia fever in puerperal
CN102283993B (en) Traditional Chinese medicine composition for treating systemic lupus erythematosus
CN104306847A (en) Six-ingredient qi-tonifying capsule and preparation process thereof
CN106581299B (en) Traditional Chinese medicine composition for improving kidney qi deficiency of middle-aged and old people and application thereof
CN101130034A (en) Traditional Chinese medicine composition for treating gland hyperplasia
CN104398958A (en) Tablet for treating leukemia
CN103393954A (en) Preparation method of ointment for helping rehabilitation of peroneal nerve injury
CN104208440B (en) A kind of Chinese medicine for the treatment of dryness of the lung phlegm stagnation type globus hystericus
CN103656199B (en) A kind of Chinese medicine for the treatment of deficiency of kidney yin syndrome cough
CN103110743B (en) Traditional Chinese medicine composition for treating or preventing neurasthenia and preparation method thereof
CN107595998B (en) Traditional Chinese medicine composition for stroke convalescence and preparation method thereof
CN102552570B (en) Medicine for treating acra necrosis after bone trauma
CN102228613B (en) Chinese patent medicine for treating tinea capitis
CN105535817A (en) A traditional Chinese medicine composition containing argy wormwood leaves and used for treating cervical spondylosis and a preparing method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151014